Cite

HARVARD Citation

    Kolehmainen, S. et al. (2021). Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting. Scandinavian journal of gastroenterology. pp. 906-913. [Online]. 
  
Back to record